GSK plc’s antibody-drug conjugate GSK'227 has received Orphan Drug Designation from the US FDA for small-cell lung cancer as of December 10, 2025, supported by positive early clinical data. This designation emphasizes the drug's potential to offer treatment options for patients with extensive-stage disease, characterized by a low 5-year survival rate of about 3%.